Advertisement
"We are pleased to have completed the Phase 1 set of human studies ofN30-201. We believe that N30-201 could be an important therapy for thetreatment of many respiratory diseases. Determining the safety of acuteadministration of N30-201 to asthmatic, as well as healthy human subjects, isan important step." commented Charles Scoggin, M.D., Chairman of N30 Pharma.
Advertisement
The primary endpoint of the study is patient safety and characterizationof adverse events, but the company collected pharmacokinetic andpharmacodynamic data of ascending doses of N30-201, including effects on theairway.
About N30-201
N30-201 is a proprietary nebulized formulation of s-nitrosoglutathione(GSNO), an endogenous bronchodilatory molecule that serves as a critical storeof nitric oxide (NO) bioactivity in the human airway.
About N30 Pharma
N30 Pharma is developing s-nitrosothiol therapies for critical unmet needsin important respiratory and cardiovascular diseases. S-nitrosothiols areendogenous molecules which store and transduce nitric oxide, and are criticalmodulators of airway and vascular smooth muscle tone. N30's drug developmentstrategy focuses on administration of GSNO to the human airway, and thedevelopment of inhibitors of GSNO reductase. GSNO reductase is the key enzymein the body that breaks down GSNO. These approaches allow N30 to delivertargeted, long lasting, physiologically relevant doses of s-nitrosothiols totarget systems. N30 is a privately held company headquartered in Boulder,Colorado.
SOURCE N30 Pharma
